Stockreport

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics, Inc.  (IKT) 
PDF BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company [Read more]